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A B S T R A C T
Background
Enteral nutrition by feeding tube is a common and efficient method of providing nutritional support to prevent malnutrition in
hospitalised patients who have adequate gastrointestinal function but who are unable to eat. Gastric feeding may be associated with
higher rates of food aspiration and pneumonia than post-pyloric naso-enteral tubes. Thus, enteral feeding tubes are placed directly into
the small intestine rather than the stomach, and the use of metoclopramide, a prokinetic agent, has been recommended to achieve post-
pyloric placement, but its efficacy is controversial. Moreover, metoclopramide may include adverse reactions, which with high doses or
prolonged use may be serious and irreversible.
Objectives
To determine the effect of intravenous metoclopramide on post-pyloric placement of the naso-enteral tube in adults.
Search methods
Trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 10) which includes the
CUGPD group’s specialised register of trials, MEDLINE (1996 to 21 October 2014), EMBASE (1988 to 21 October 2014), LILACS
(2005 to 21 October 2014) We did not confine our search to English language publications. Searches in all databases were updated
originally in January 2005, then in November 2008 and again in October 2014. No new studies were found in 2008 or in 2014.
Selection criteria
We selected randomised controlled trials of adults needing enteral nutrition, who received intravenous or intramuscular metoclopramide
to aid placement of transpyloric naso-enteral feeding tubes, compared to placebo or no intervention.
Data collection and analysis
We used standard methodological procedures expected by The Cochrane Collaboration. All analyses were performed according to the
intention-to-treat method. We present risk ratios (RR) with 95% confidence intervals (CI).
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Main results
Four studies, with a total of 204 participants were included and analysed. The trials compared metoclopramide with placebo (two
trials) or with no intervention (two trials). Metoclopramide was investigated at doses of 10 mg (two trials) and 20 mg (two trials).
There was no statistically significant difference between metoclopramide versus placebo or no intervention administered to promote
tube placement (RR 0.82, 95% CI 0.61 to 1.10). Metoclopramide at doses of 10 mg (RR 0.82, 95% CI 0.60 to 1.11) and 20 mg
(RR 0.62, 95% CI 0.15 to 2.62) were equally ineffective in facilitating post-pyloric intubation when compared with placebo or no
intervention.
Authors’ conclusions
In this review, we found only four studies that fitted our inclusion criteria. These were small, underpowered studies, in which meto-
clopramide was given at doses of 10 mg and 20 mg. Our analysis showed that metoclopramide did not assist post-pyloric placement
of naso-enteral feeding tubes.
Ideally randomised clinical trials should be performed that have a significant sample size, administering metoclopramide against control,
however, given the lack of efficacy revealed by this review it is unlikely that further studies will be performed.
P L A I N L A N G U A G E S U M M A R Y
Metoclopramide for accurate placement of naso-enteral feeding tube
Background
When a person is unwell and is unable to eat (or to eat enough), the lack of nutrition can be a serious obstacle to recovery. In these
circumstances, feeding through a feeding tube that enters through the nose and passes through the stomach to the small intestine
beyond (a post-pyloric naso-enteral feeding tube), is an option.
Review question
Once the feeding tube has entered the digestive system, placing the feeding tube into the small intestine rather than the stomach is
difficult. Metoclopramide (which is also an anti-sickness medication), increases the rate at which the stomach empties, and has tested
as a therapy to determine whether it assists with placement of post-pyloric naso-enteral feeding tubes.
Use of metoclopramide is controversial, as it may cause harms (adverse reactions), which may be serious and may include an irreversible
neurological condition that can be caused by prolonged use, or high doses of metoclopramide.
Study characteristics
We originally searched for clinical trials in 2002; and again in 2008 and 2014. We identified four studies that investigated the use
of metoclopramide in placement of post-pyloric naso-enteral feeding tubes. The trials included a total of 204 adult participants; 108
participants were treated with metoclopramide, and 96 were given a placebo or no treatment. All four studies were done in hospitals
in the USA. The number of participants included in the trials varied from 105 to 10.
The trials were all performed before 1995. They were all small, and examined two different doses of metoclopramide (10 mg and 20
mg), delivered in two different ways (intravenously, and injected into muscle). The way in which they were conducted and reported
was poor.
Key results
Analysis of the four trials revealed that metoclopramide did not have a clear beneficial on the placement of post-pyloric naso-enteral
feeding tubes. No harms (adverse reactions) were reported, though it was not clear how thoroughly the people running the trials
recorded them. No costs of treatment were reported.
Quality of the evidence
The quality of the evidence is very low. The four trials were too small to identify any effect clearly; they also used different doses of
metoclopramide, (tested against placebo or no treatment). It is unlikely that further studies will be performed to establish whether
metoclopramide is helpful in placement of post-pyloric naso-enteral feeding tubes.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Metoclopramide for post-pyloric placement of enteral feeding tubes
Patient or population: patients needing post-pyloric placement of naso-enteral feeding tubes
Settings: hospital
Intervention: metoclopramide
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Metoclopramide
Failure rate of post-py-
loric placement of the
enteral feeding tube as-
sessed by abdominal ra-
diograph
Radiographic
assessment of success-
ful tube placement
Follow-up: mean 4 hours
Study population RR 0.82
(0.61 to 1.1)
204
(4 studies)
⊕©©©
very low1,2,3,4
562 per 1000 461 per 1000
(343 to 619)
Moderate
572 per 1000 469 per 1000
(349 to 629)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality: we are very uncertain about the estimate
1 Design limitation (risk of bias)
2 Statistical heterogeneity present in the analyses of trials comparing 20 mg metoclopramide versus control
3 Small number of trials with relatively few participants/events
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B A C K G R O U N D
Description of the condition
Enteral nutrition by feeding tube is a common and efficient
method of providing nutritional support to prevent malnutrition
in hospitalised patients who have adequate gastrointestinal func-
tion but who are unable to eat. Post-pyloric naso-enteral feeding
tubes, that enter through the nasal passages and deliver food di-
rectly to the duodenum or jejunum, have lower incidence of com-
plications compared to naso-gastric tubes - which deliver food to
the stomach - because of their lower rate of gastroesophageal re-
flux, regurgitation, excessive salivation and irritation of the mu-
cosas. This can be uncomfortable for the patient and also increases
the risk of aspiration of food, which can lead to pneumonia. Post-
pyloric feeding tube (catheter) placement is not straightforward,
but is easier when using manoeuvres such as putting patients in
the right-sided lateral position or stimulating them to walk. A
stimulating gastric motility drug such as metoclopramide has been
used as an auxiliary therapy to promote tube placement. Meto-
clopramide could also be applied in cases where the tube has suc-
cessfully entered the digestive system through the throat and into
the oesophagus (gullet) and stomach but migration of the tube
through the pyloric sphincter (between the stomach and duode-
num) is delayed (Troncon 2000).
Description of the intervention
Metoclopramide is a gastrointestinal stimulant and anti-sickness
(antiemetic) drug, which increases the gastric emptiness (Sumner
1986). Metoclopramide has a local stimulating effect on gastric
motility and causes the acceleration of gastric emptiness without
any concomitant secretion of gastric acid. It is useful for treating
gastroesophageal reflux and in disorders of gastric emptiness, but
not in the paralytic ileum (Rang 1997).
One study has demonstrated that metoclopramide is useful in
post-pyloric feeding tube placement in diabetic patients, increas-
ing the frequency of successful post-pyloric intubation in these
patients, but not in non-diabetic patients (Kittinger 1987). In
another small study comparing placebo, metoclopramide treat-
ment after tube placement, and metoclopramide treatment before
tube placement, duodenal intubation occurred in 90% of patients
who received metoclopramide before feeding tube introduction
(Kalfarentzos 1987). Metoclopramide is not effective when ad-
ministered after tube introduction (Whatley 1984). Additionally,
metoclopramide may be associated with adverse events, for exam-
ple, Heiselman 1995 indicated that restlessness, drowsiness, agi-
tation, rashes (urticaria) and occasional drug-induced movement
disorders (extrapyramidal reactions) may occur when using meto-
clopramide at a dose of 20 mg.
Why it is important to do this review
As there is no systematic review evaluating the effectiveness of
parenteral metoclopramide, we will try to answer the following
question: is metoclopramide effective and safe for the post-pyloric
placement of naso-enteral feeding tubes?
O B J E C T I V E S
To determine the effect of intravenous metoclopramide on post-
pyloric placement of the naso-enteral tube in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing metoclopramide
with placebo or no intervention for the placement of naso-enteral
tubes. RCTs were included irrespective of publication status, lan-
guage or blinding.
Types of participants
Participants were all adults (over 18 years of age) receiving par-
enteral metoclopramide for introduction of enteral feeding tube.
Types of interventions
Metoclopramide against placebo or no intervention.
Types of outcome measures
Primary outcomes
• Success rate of post-pyloric placement of the naso-enteral
feeding tube.
Secondary outcomes
Adverse reactions including:
• depression;
• high blood pressure;
• decrease of libido;
• headache;
• skin rash;
• fatigue;
• fever;
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• hyperactivity;
• insomnia;
• nausea;
• sedation;
• tremor and agitation in the hand;
• dyslalia (speech difficulties);
• dysphagia (swallowing problems).
Search methods for identification of studies
Electronic searches
Trials were identified by searching:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2014, Issue 10; Appendix 1), which includes the
CUGPD group’s specialised register of trials;
• MEDLINE (1996 to 21 October 2014; Appendix 2);
• EMBASE (1988 to 21 October 2014; Appendix 3);
• LILACS (2005 to 21 October 2014; Appendix 4).
We did not confine our search to English language publications.
Searches in all databases were updated in January 2005 and up-
dated again in November 2008 and October 2014. No new stud-
ies were found by the searches in 2008, or in October 2014.
Searching other resources
We handsearched reference lists from trials selected by electronic
searches to identify further relevant trials.
In addition, we contacted members of the Cochrane Upper Gas-
trointestinal and Pancreatic Diseases (UGPD) review Group, ex-
perts in the field, editors of relevant journals and pharmaceutical
companies involved in the production of metoclopramide to ask
them to supply details of any outstanding clinical trials and rele-
vant unpublished materials.
Data collection and analysis
Selection of studies
Two reviewers (CCRS and HS) applied the inclusion criteria to
all potential randomised studies. For this updated review CB and
CCRS reviewed the results of the updated searches and applied
the inclusion criteria to all potential randomised studies.
Review authors were not blinded to the reporting of authors’
names, journals, date of publication, sources of financial support
or results.
Data extraction and management
Two reviewers (CCRS, HS with CB) independently extracted the
following pre-specified characteristics of all includedRCTs. In case
of discrepancy, the opinion of a fourth reviewer was sought in
order to reach a consensus. We extracted data on the: methods,
including diagnostic procedure, baseline evaluation of the ade-
quate primary outcomes, and reliability of the outcome measures,
complete follow-up; the participants, including age, indication for
naso-enteral intubation, number of randomised patients; the in-
tervention dosage, co-intervention in the control group, and route
and timing of administration; and outcomes, that is success rate of
post-pyloric placement into the duodenum and adverse reactions.
Assessment of risk of bias in included studies
In this updated review, we independently assessed the risk of bias
of the included studies using the risk of bias assessment tool de-
scribed in Chapter 8 of theCochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). We compared the evalua-
tions, and discussed and resolved any inconsistencies between the
review authors’ decisions.
We rated the following domains separately for each of the included
studies as ’low risk of bias’, ’high risk of bias’, and ’unclear’ when
the risk of bias was uncertain or unknown:
• generation of allocation sequence (’sequence generation’);
• concealment of allocation (’allocation concealment’);
• prevention of knowledge of the allocated interventions
during the study (’blinding’);
• methods used to address incomplete outcome data;
• selective outcome reporting;
• other sources of bias that could put a study at high risk of
bias, including whether a calculation of sample size was carried
out.
These assessments are reported in the ’Risk of bias’ table for each
individual study in the ’Characteristics of included studies’ section
of the review, and in the ’Risk of bias in included studies’ section
of this review.
Measures of treatment effect
We presented dichotomous outcomes data as risk ratios (RR) with
their associated 95% confidence intervals; these were analysed in
Review Manager 5.3 using the Mantel-Haenszel test and a ran-
dom-effects model (RevMan 2014), unless stated otherwise.
Unit of analysis issues
We did not expect any cross-over trials, as it is unlikely that the
participants would be crossed-over to receive an alternative inter-
vention.
If we encountered a multi-armed study, we planned to use data
only from the metoclopramide arm versus placebo.
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Dealing with missing data
We attempted to contact investigators to retrieve missing data. We
analysed all data by the intention-to-treat method.
Assessment of heterogeneity
We assessed clinical heterogeneity by examining the trial condi-
tions, that is, the characteristics of the studies, the similarity be-
tween the types of participants, and the interventions.
Statistical heterogeneity was assessed both by calculation of stan-
dard Chi2 test and defined as significant when the P value was less
than 0.1. When we found heterogeneity we explored the potential
causes.
Assessment of reporting biases
Weplanned to carry out assessments of reporting bias when at least
ten studies were included in a meta-analysis, following the recom-
mendations on testing for funnel plot asymmetry as described in
section 10.4.3.1 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We planned to explore possible
sources of asymmetry with an additional sensitivity analysis, but
in this review we did not have enough included studies to make
such analyses feasible.
Data synthesis
All analyses were performed according to the intention-to-treat
method.
We used Review Manager (RevMan 2014), which is the soft-
ware package provided by Cochrane Collaboration. For dichoto-
mous variables, risk ratio was calculated by random-effects model
(DerSimonian 1986). If the overall results had been statistically sig-
nificant, we planned to calculate the relative risk reduction (RRR),
the number needed to treat for an additional beneficial outcome
(NNTB) and the number needed to treat for an additional harm-
ful outcome (NNTH).
Subgroup analysis and investigation of heterogeneity
We explored statistical heterogeneity differences in reported ef-
fects, methodological heterogeneity, differences in study design
and clinical heterogeneity differences between studies in partici-
pants characteristics, interventions or outcome measures (Higgins
2011).
We made a post hoc decision to conduct subgroup analyses on the
basis of metoclopramide dosage.
Sensitivity analysis
There were too few included studies in this review to permit sen-
sitivity analysis.
R E S U L T S
Description of studies
Results of the search
Nineteen potential studies were identified by electronic and man-
ual searches up to October 2014. A further 58 potential studies
were identified from electronic searches in 2014, but no new trials
were identified for inclusion at this update (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
We found four RCTs enrolling a total of 204 participants
(Heiselman 1995; Kittinger 1987; Seifert 1987; Whatley 1984;
Characteristics of included studies). Of the 204 participants, 108
were treated with metoclopramide, and 96 received placebo or
no treatment. Participants designated to undergo treatment with
metoclopramide were compared with those allocated to receive
placebo or no treatment.
Participants
The studies included only adult participants. All four included
studies were carried out in a secondary care environment, and
all were conducted in the USA. Sample sizes varied from 105 in
Heiselman 1995, to 70 in Kittinger 1987, 19 in Seifert 1987, and
10 in Whatley 1984.
The Heiselman 1995 study included patients in the critical care
unit who required enteral nutrition. In Kittinger 1987 all the par-
ticipants required feeding tube placement, but pregnant in-pa-
tients and intensive care patients were excluded. In Seifert 1987 all
patients requiring additional nutrition were eligible for the trial,
except for pregnant in-patients and patients currently receiving
metoclopramide or neuroleptic patients. TheWhatley 1984 study
included patients that had previously had failed duodenal intu-
bation. We also collected data on whether diabetic patients were
included; Kittinger 1987 included diabetic patients, but this in-
formation was not provided in Heiselman 1995, Seifert 1987 or
Whatley 1984.
Intervention
Metoclopramide was given intravenously in three studies (
Heiselman 1995; Seifert 1987; Whatley 1984). In one study
metoclopramide was given intramuscularly (Kittinger 1987). Two
studies compared metoclopramide with placebo (Kittinger 1987;
Seifert 1987), while in the other two studies the control group did
not receive any intervention (Heiselman 1995; Whatley 1984).
Comparison
Metoclopramide versus placebo (Kittinger 1987; Seifert 1987), or
no intervention (Heiselman 1995; Whatley 1984).
Outcomes
All studies analysedwhethermetoclopramide improved the success
rate of post-pyloric feeding tube placement. This was identified
by ausculation and abdominal radiography in Heiselman 1995,
and by abdominal radiography alone in Kittinger 1987, Seifert
1987 and Whatley 1984. Success rate of transport of pyloric tube
placementwas evaluated 45minutes after placement inHeiselman
1995; four hours after insertion of the feeding tube in Seifert 1987
and Whatley 1984; and with an additional abdominal radiograph
24 hours later in some patients who receivedmetoclopramide after
feeding tube insertion. In Kittinger 1987, the success rate was
evaluated by abdominal radiography one hour after insertion of
the feeding tube.
Excluded studies
Fifteen studies did not fit the inclusion criteria and were not in-
cluded in this systematic review (see Characteristics of excluded
studies).
Risk of bias in included studies
The risk of bias of included studies is summarised in Figure 2 and
Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
Allocation
Allocation concealment
There were no descriptions of allocation concealment in the in-
cluded studies.
Generation of allocation sequence
Two studies used a randomnumber table to generate the allocation
sequence (Kittinger 1987; Whatley 1984). Heiselman 1995 and
Seifert 1987 did not describe the allocation method used, they
simply indicated that the studies were randomised.
Blinding
Two studies were described as double-blind (Seifert 1987;
Kittinger 1987), however full details of how this was achievedwere
not given in the published report of the Kittinger 1987 study. It is
therefore unclear whether participants, personnel and outcome as-
sessors were adequately blinded. In Seifert 1987, the participants,
nurses investigators and radiologists were blinded to the treatment
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protocol. In the remaining two studies there was no description
of double-blind methods and we rated these as being at high risk
of bias for this domain.
Placebo description
Two studies reported a placebo of identical appearance (Kittinger
1987, Seifert 1987).
Incomplete outcome data
Three studies did not have withdrawals or dropouts. One study
had withdrawal and reasons of withdrawal were described, but the
analysis was not performed on an intention-to-treat basis (Seifert
1987).
Selective reporting
We rated all studies as being at low risk for selective reporting,
as outcomes were reported, however we did not have access to
the original trial protocols and we were therefore unable to assess
whether there were any unpublished outcomes.
Other potential sources of bias
Sample size calculation
Only one study reported sample size calculation (Heiselman
1995).
Effects of interventions
See: Summary of findings for the main comparison
Metoclopramide for post-pyloric placement of enteral feeding
tubes
Metoclopramide versus control (placebo or no
intervention)
Failure rate of post-pyloric placement of enteral feeding tube
In an analysis comparing metoclopramide 10 mg with control
(Heiselman 1995; Kittinger 1987), failure of post-pyloric tube
placement of the enteral feeding tube was observed in 41 out of
94 participants (43.7%) using metoclopramide compared with 43
out of 81 (53%) in the control groups. There was no statistically
significant difference between the groups (RR 0.82, 95% CI 0.60
to 1.11; 175 participants; 2 studies; Analysis 1.1). In this com-
parison there was no statistically significant heterogeneity (Chi2 =
0.06, degrees of freedom (df ) = 1, P value 0.81).
In an analysis of studies that used metoclopramide 20 mg versus
control (Seifert 1987; Whatley 1984), failure of post-pyloric tube
placement was observed in 7 out of 14 participants in themetoclo-
pramide group (50%) compared with 11 out of 15 in the control
group (73%); this difference was not statistically significant (RR
0.62, 95% CI 0.15 to 2.62; 29 participants; 2 studies; Analysis
1.1).Heterogeneity was observed in this comparison (Chi2 = 3.48,
df = 1, P value 0.06).
When we pooled all four trials independent of dosage, the failure
rate was 44% (48/108) in the metoclopramide group compared
with 56% (54/96) in the control group (RR 0.82, 95% CI 0.61 to
1.10; 204 participants; 4 studies; Analysis 1.1). In this comparison
there was no statistically significant heterogeneity (Chi2 = 3.24,
df = 3, P value 0.36).
Sensitivity analysis
As there were only four studies with a total of 204 participants,
we did not perform sensitivity analysis or investigate publication
bias using a funnel plot.
Adverse effects
Seifert 1987 reported that no adverse effects attributable to either
metoclopramide or placebo were observed. Kittinger 1987 did
not report any adverse effects. Whatley 1984 reported that there
were no ’side effects’ of metoclopramide noted in any participants.
Heiselman 1995 noted that adverse effects could include drowsi-
ness, anxiety, agitation and urticaria, and rarely extrapyramidal
effects, but did not report adverse effects directly attributable to
metoclopramide administered in the course of that study.
D I S C U S S I O N
Summary of main results
Whatley1984 showed thatmetoclopramide improves gastric emp-
tying by increasing the amplitude of gastric contractions while re-
laxing the pyloric sphincter and the duodenal bulb and recorded
a significant increase in post-pyloric intubation when metoclo-
pramide was administered prior to the tube insertion. Although
that study showed significant results, in our systematic review of
four studies, we observed that metoclopramide was not effective
in improving the success rate for post-pyloric migration of the en-
teral tube.
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Overall completeness and applicability of
evidence
The four studies included in this systematic review demonstrate
that metoclopramide, as administered, did not facilitate post-py-
loric intubation in adults. However, the RCTs included had small
sample sizes, therefore, we cannot rule out a beneficial effect of
metoclopramide. Just one RCT reported thatmetoclopramide was
effective (Whatley 1984). Subgroup analysis in the Kittinger 1987
study, demonstrated that metoclopramide was effective only for
people with diabetes mellitus and with evident neuropathy. The
other two studies did not find any beneficial effect of metoclo-
pramide (Heiselman 1995; Seifert 1987).
Statistical heterogeneity was found in the comparison of metoclo-
pramide at a dosage of 20 mg. This may be explained by clinical
heterogeneity between the studies. The failure rates between the
two studies were very different. In the Seifert 1987 study there was
a very similar rate between metoclopramide and placebo, whereas
in the Whatley 1984 study, the failure rate was lower in the meto-
clopramide group, at 20%, compared with 100% of those receiv-
ing placebo. Other potential sources of heterogeneity were the
poor methodological quality of the studies; use of placebo and
double-blinding in one study (Seifert 1987); and no intervention
and no blinding for the control group in the other study (Whatley
1984).
None of our included studies provided detailed information about
adverse effects. Only one study (Heiselman 1995) noted the types
of adverse effects that can occur due to metoclopramide but did
not report adverse effects directly attributable to metoclopramide
administered in the course of that study.
Peoplewho are givenmetoclopramide, especially at doses of 20mg,
may experience adverse reactions which may include depression,
high blood pressure, decrease of libido, headache, skin rash, fa-
tigue, fever, hyperactivity, insomnia, nausea, sedation, drowsiness,
agitation, and extrapyramidal reactions (impaired speech or im-
paired swallowing, unsteady gait, inflexibility of upper and lower
members, tremor). A recent publication also warns of the risk of
developing tardive dyskinesia, or involuntary and repetitive move-
ments of the body, with long-term or high-dose use of metoclo-
pramide (EMA 2013; FDA 2009).
Quality of the evidence
Potential sources of bias in studies analysing the effect of meto-
clopramide at the dosage 10 mg for post-pyloric migration of the
enteral tube are the timing and methods to evaluate the outcomes;
differences in the positioning of patients during the passage of the
tube; and ability and experience of the nurse or physician, since
training is a factor associated with the successful passage of the
naso-enteral tube (Heiselman 1995). Since there were no differ-
ences between these studies in relation to timing, administration
and dosage of metoclopramide, these explanations do not seem to
justify the heterogeneity observed in these comparisons.
We should, therefore, emphasise that any conclusions we have
drawn rely on only four primary studies that had a varying degree
of bias due to limitations in trial design. The risk of bias should be
considered when interpreting these results (Figure 2), and, given
that the findings derive from studies with a high or unclear risk
of bias, the findings reported in each study should be viewed with
caution.
Overall, the quality of evidence in each comparison was rated as
very low and the current body of evidence does not allow ro-
bust conclusions to be drawn concerning the efficacy of meto-
clopramide in assisting post pyloric placement of enteral feeding
tubes.
Potential biases in the review process
We attempted tominimise publication bias by conducting exhaus-
tive searches for trials, however only four studies fitted our inclu-
sion criteria. These were published between 1984 and 1995, with
none published since, so we were able to conduct only one meta-
analysis. Sensitivity analysis was not possible for primary outcome
measures for studies at low risk of bias, as there were too few such
studies to permit us to assess the results of the review in this way.
Agreements and disagreements with other
studies or reviews
Whatley 1984 reported that metoclopramide treatment before
tube placement was superior to no drug in a small study, however,
in the analysis that we carried out using data from four randomised
controlled trials including Whatley 1984, in this review, we con-
cluded that metoclopramide was not effective in facilitating post-
pyloric placement of naso-enteral feeding tubes.
A network meta-analysis of RCTs of methods to promote place-
ment of post-pyloric feeding tubes, including prokinetic agents
(metoclopramide and erythromycin) and gastric air insufflation,
was published recently (Huang 2014). The findings of that anal-
ysis were broadly in agreement with our study, in that the authors
concluded that none of the methods reached statistical signifi-
cance and that the use of a prokinetic agent might induce more
potential adverse reactions. The authors of Huang 2014 recom-
mended that clinicians in clinical practice should no longer use
prokinetic agents for this purpose in either paediatric patients or
in patients without impaired gastric motility. They also stated that
gastric insufflation seems to be clinically better for promoting bed-
side placement of post-pyloric feeding tubes in adults but in their
analysis the results for gastric insufflation did not reach statistical
significance compared with other methods, and there are addi-
tional safety concerns with this method. It may in fact be that no
technique is superior to the standard technique which is bedside
placement performed blindly. The authors of Huang 2014 con-
13Metoclopramide for post-pyloric placement of naso-enteral feeding tubes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
cluded that more large, well-designed RCTs focusing on special
populations were required to determine if there are methods that
work better than endoscopic placement.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We identified no evidence to suggest that metoclopramide en-
hanced the post-pyloric placement of naso-enteral feeding tubes.
None of the studies included in this review specifically addressed
adverse effects, and information related to adverse effects can only
be derived from reports of studies using metoclopramide for other
conditions, which are outside the scope of this review. Adverse
events related to long term or high dose use of metoclopramide
may include irreversible neurological changes (EMA 2013; FDA
2009)
The Included studies were small and underpowered, used different
doses of metoclopramide, and the overall quality of the evidence
was very low, with a high risk of bias in several important features
of the trials’ designs.
Implications for research
If future research is carried out, it should take the form of well de-
signed and conducted randomised controlled trials (Moher 2001),
with a participant population of significant size, administering
metoclopramide versus placebo, control or an alternative inter-
vention. Future research would help to evaluate the efficacy of in-
travenous metoclopramide to facilitate post-pyloric intubation of
naso-enteral tubes and establish possible factors of migration (abil-
ity and experience of the nurse or physician, decubitus position-
ing during the passage of the tube, metoclopramide). Participant
characteristics should be reported tominimise clinical heterogene-
ity within the sample. The intervention should compare standard
doses of metoclopramide either intravenously or intramuscularly.
Post-pyloric intubation should be evaluated by abdominal X-rays
within four hours of metoclopramide administration.
The known safety profile of metoclopramidemeans that recording
of adverse events should be a primary outcome of such studies.
Given the safety profile and apparent lack of efficacy of this inter-
vention, however, further studies are unlikely to be carried out.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Heiselman 1995
Methods RCT
Participants Number of participants randomised: 105; 46 in the control group and 59 in the meto-
clopramide group
Inclusion criteria: admission to the critical care unit; need for enteral nutrition
Did not state whether diabetic patients were included or not
Interventions • 59 participants received metoclopramide 10 mg intravenously 10 minutes prior to
the insertion of the naso-enteral tube
• 46 control participants received no medication prior to the insertion of the naso-
enteral tube
Outcomes Success rate of post-pyloric tube placement evaluated by auscultation of the right upper
abdominal quadrant and abdominal radiography taken 45 minutes after tube advance-
ment
Notes Setting: Ohio, USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details about randomisation provided
Allocation concealment (selection bias) Unclear risk Concealment of allocation sequence not described
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding of participants, personnel or outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no withdrawals or dropouts
Selective reporting (reporting bias) Unclear risk All outcomes reported
Other bias Low risk Sample size calculation was reported
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Kittinger 1987
Methods RCT
Participants Number of participants randomised: 70
Inclusion criteria: all patients requiring feeding tube placement were considered eligible,
including diabetic patients
Exclusion criteria: pregnant in-patients and intensive care patients
Interventions • 35 participants received metoclopramide 10 mg in 2 ml volume intramuscularly
• 35 participants received 2 ml of diluent as placebo.
Either metoclopramide or placebo was administered immediately after insertion of the
feeding tube
Outcomes Success rate of post-pyloric tube placement evaluated by abdominal radiography 1 hour
after insertion of the feeding tube
Notes Setting: North Carolina,USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generation of the allocation sequence: random number table
Allocation concealment (selection bias) Unclear risk Concealment of allocation sequence not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double-blind method: not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk There are no withdrawals or dropouts
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Sample size calculation was not reported
Seifert 1987
Methods RCT
Participants Number of participants randomised: 19
Inclusion criteria: all patients requiring naso-enteral nutrition were considered eligible
Exclusion criteria: pregnant in-patients or patients currently receiving metoclopramide
or neuroleptic agents
It was not stated whether diabetic patients were included or not
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Seifert 1987 (Continued)
Interventions • 7 participants received metoclopramide 20 mg in 4 ml volume intravenously
• 9 participants received 4 ml of normal saline as placebo
Either metoclopramide or placebo were administered 15 minutes prior to the insertion
of the naso-enteral tube
Outcomes Success rate of post-pyloric tube placement evaluated by abdominal radiography 4 hours
after insertion of the feeding tube
Notes Setting: USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the allocation sequence: not described
Allocation concealment (selection bias) Unclear risk Concealment of allocation sequence not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind method: the patients, registered nurses, investiga-
tors and radiologists were blinded to the treatment protocol
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons were provided for withdrawals and dropouts. 1 partici-
pant was lost due to the accidental removal of the tube before the
medication was taken and 1 was lost from each group before the
X-ray to determine to determine correct placement had taken
place
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Intention-to-treat analysis: no
Sample size calculation was not reported
Whatley 1984
Methods RCT
Participants Number of participants randomised:
• 12 were included in the non-randomised pilot study
• a second group of 10 patients (5 in each group) were randomised to receive
metoclopramide or placebo
Inclusion criteria: all 22 patients that had failed to achieve spontaneous duodenal intu-
bation were considered eligible
Exclusion criteria: no clearly described
It was not stated whether diabetic patients were included or not
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Whatley 1984 (Continued)
Interventions In the randomised comparison:
• 5 participants received 20 mg of metoclopramide intravenously 10 minutes prior
to the reinsertion of weighted tubes
• 5 control participants did not receive any intervention
Outcomes Success rate of post-pyloric tube placement evaluated by abdominal radiography 4 hours
after insertion of the feeding tube. In participants who received metoclopramide after
feeding tube insertion, an additional abdominal radiography was also obtained 24 hours
later
Notes Setting: USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generation of the allocation sequence: random number table
Allocation concealment (selection bias) Unclear risk Concealment of allocation sequence not described
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding of participants, personnel or outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no withdrawals or dropouts
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Sample size calculation was not reported
Abbreviation
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Beau 1995 Examined the techniques for enteral nutrition, was not an RCT
Gottschlich 1996 Not an RCT
Kalfarentzos 1987 Not an RCT
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(Continued)
Kalliafas 1996 Determined whether administration of erythromycin could facilitate passage of a nasoenteric feeding tube to
the duodenum for post-pyloric feeding
Keshavarzian 1993 Not an RCT, was a crossover study
Kirby 1995 Not an RCT
Levenson 1986 Compared the frequency of duodenal intubations using weighted and un-weighted nasoenteric feeding tubes
Levy 1988 Not an RCT
Lord 1992 Compared passage of weighted versus un-weighted enteral feeding tubes
Marian 1993 Not an RCT, was a prospective study.
Schmieding 1997 Not an RCT
Schulz 1993 Not an RCT, was a prospective study
Stern 1994 Determined whether erythromycin ethylsuccinate elixir would facilitate the post-pyloric passage
Thurlow 1985 Not an RCT
Ugo 1992 Not an RCT
Abbreviation
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Metoclopramide versus placebo or no intervention for post-pyloric placement of enteral feeding
tubes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Failure rate of transpyloric
placement of the enteral
feeding tube assessed by
abdominal radiograph
4 204 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.61, 1.10]
1.1 Metoclopramide 10 mg 2 175 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.60, 1.11]
1.2 Metoclopramide 20 mg 2 29 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.15, 2.62]
Analysis 1.1. Comparison 1 Metoclopramide versus placebo or no intervention for post-pyloric placement
of enteral feeding tubes, Outcome 1 Failure rate of transpyloric placement of the enteral feeding tube assessed
by abdominal radiograph.
Review: Metoclopramide for post-pyloric placement of naso-enteral feeding tubes
Comparison: 1 Metoclopramide versus placebo or no intervention for post-pyloric placement of enteral feeding tubes
Outcome: 1 Failure rate of transpyloric placement of the enteral feeding tube assessed by abdominal radiograph
Study or subgroup Metoclopramide Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Metoclopramide 10 mg
Heiselman 1995 27/59 25/46 49.2 % 0.84 [ 0.57, 1.24 ]
Kittinger 1987 14/35 18/35 29.1 % 0.78 [ 0.46, 1.31 ]
Subtotal (95% CI) 94 81 78.3 % 0.82 [ 0.60, 1.11 ]
Total events: 41 (Metoclopramide), 43 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
2 Metoclopramide 20 mg
Seifert 1987 6/9 6/10 17.4 % 1.11 [ 0.56, 2.20 ]
Whatley 1984 1/5 5/5 4.3 % 0.27 [ 0.07, 1.11 ]
Subtotal (95% CI) 14 15 21.7 % 0.62 [ 0.15, 2.62 ]
Total events: 7 (Metoclopramide), 11 (Control)
Heterogeneity: Tau2 = 0.79; Chi2 = 3.48, df = 1 (P = 0.06); I2 =71%
0.001 0.01 0.1 1 10 100 1000
Favours metoclopramide Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Metoclopramide Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 108 96 100.0 % 0.82 [ 0.61, 1.10 ]
Total events: 48 (Metoclopramide), 54 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.24, df = 3 (P = 0.36); I2 =7%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours metoclopramide Favours control
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
OVID EBM Reviews - Cochrane Central Register of Controlled Trials <September 2014>
1 exp enteral nutrition/ (1307)
2 (enter$ adj3 feed$).tw. (864)
3 (enter$ adj3 nutrit$).tw. (1837)
4 or/1-3 (2879)
5 exp Intubation, Gastrointestinal/ (527)
6 (nasoenteral$ or naso enteral$).tw. (16)
7 (esophag$ adj3 intubat$).tw. (64)
8 (oesophag$ adj3 intubat$).tw. (54)
9 (duoden$ adj3 intubat$).tw. (28)
10 (gastrointest$ adj3 intubat$).tw. (4)
11 (gastric adj3 intubat$).tw. (70)
12 (esophag$ adj3 catheter$).tw. (40)
13 (oesophag$ adj3 catheter$).tw. (18)
14 (duoden$ adj3 catheter$).tw. (6)
15 (stomach adj3 intubat$).tw. (12)
16 (stomach adj3 catheter$).tw. (7)
17 (gastrointest$ adj3 catheter$).tw. (3)
18 (gastric adj3 catheter$).tw. (19)
19 exp gastrointestinal motility/ (2442)
20 exp gastric emptying/ (1141)
21 (stomach adj3 emptying).tw. (97)
22 (gastric adj3 emptying).tw. (1870)
23 (gastro$ adj3 motili$).tw. (413)
24 (gastric adj3 motili$).tw. (306)
25 or/5-24 (4251)
26 exp metoclopramide/ (954)
23Metoclopramide for post-pyloric placement of naso-enteral feeding tubes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
27 (Metoclopramide or Cerucal or 5 Chloro 2 Methoxyprocainamide or Clodilion or Clopra or Del 1267 or Del1267 or Diber-
til or Duraclamid or Emenil or Emetard or Emitasol or Encil or Gastrobid or Gastronerton or Gastrosil or Gastrotem or Gastro
Timelets or Gastrotimelets or Hyrin or M 813 or M813 or Maxeran or Maxeron or Maxolan or Maxolon or Meclopamide or Meclo-
pramide or Meclopran or Metaclopramide or Methochlopramide or Methoclopramide or Methoclopramine or Metochlopramide or
Metoclopamide or Metoclopramid or Metoclopramine or Metoclopranide Hydrochloride or Metaclopromide or Metoclorpramide or
Metodopramide or Metopram or Metox or Metpamid or Mygdalon or Neu Sensamide or Octamide or Paspertin or Perinorm or Plasil
or Pramidin or Pramin or Primperan or Reclomide or Reglan or Rimetin or Sensamide or Tomid).tw. (1717)
28 or/26-27 (1783)
29 4 and 25 and 28 (22)
Appendix 2. MEDLINE search strategy
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>
1 randomized controlled trial.pt. (397350)
2 controlled clinical trial.pt. (90496)
3 randomized.ab. (316885)
4 placebo.ab. (162975)
5 drug therapy.fs. (1775294)
6 randomly.ab. (227206)
7 trial.ab. (330636)
8 groups.ab. (1429199)
9 or/1-8 (3509100)
10 exp animals/ not humans.sh. (4077582)
11 9 not 10 (3013932)
12 exp enteral nutrition/ (16146)
13 (enter$ adj3 feed$).tw. (5972)
14 (enter$ adj3 nutrit$).tw. (6942)
15 or/12-14 (20878)
16 exp Intubation, Gastrointestinal/ (8571)
17 (nasoenteral$ or naso enteral$).tw. (139)
18 (esophag$ adj3 intubat$).tw. (601)
19 (oesophag$ adj3 intubat$).tw. (242)
20 (duoden$ adj3 intubat$).tw. (382)
21 (gastrointest$ adj3 intubat$).tw. (52)
22 (gastric adj3 intubat$).tw. (984)
23 (esophag$ adj3 catheter$).tw. (376)
24 (oesophag$ adj3 catheter$).tw. (100)
25 (duoden$ adj3 catheter$).tw. (260)
26 (stomach adj3 intubat$).tw. (120)
27 (stomach adj3 catheter$).tw. (84)
28 (gastrointest$ adj3 catheter$).tw. (43)
29 (gastric adj3 catheter$).tw. (259)
30 exp gastrointestinal motility/ (33836)
31 exp gastric emptying/ (9078)
32 (stomach adj3 emptying).tw. (442)
33 (gastric adj3 emptying).tw. (10373)
34 (gastro$ adj3 motili$).tw. (4222)
35 (gastric adj3 motili$).tw. (2905)
36 or/16-35 (50241)
37 exp metoclopramide/ (4635)
38 (Metoclopramide or Cerucal or 5 Chloro 2 Methoxyprocainamide or Clodilion or Clopra or Del 1267 or Del1267 or Diber-
til or Duraclamid or Emenil or Emetard or Emitasol or Encil or Gastrobid or Gastronerton or Gastrosil or Gastrotem or Gastro
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Timelets or Gastrotimelets or Hyrin or M 813 or M813 or Maxeran or Maxeron or Maxolan or Maxolon or Meclopamide or Meclo-
pramide or Meclopran or Metaclopramide or Methochlopramide or Methoclopramide or Methoclopramine or Metochlopramide or
Metoclopamide or Metoclopramid or Metoclopramine or Metoclopranide Hydrochloride or Metaclopromide or Metoclorpramide or
Metodopramide or Metopram or Metox or Metpamid or Mygdalon or Neu Sensamide or Octamide or Paspertin or Perinorm or Plasil
or Pramidin or Pramin or Primperan or Reclomide or Reglan or Rimetin or Sensamide or Tomid).tw. (5631)
39 or/37-38 (6628)
40 15 and 36 and 39 (63)
41 11 and 40 (39)
42 limit 41 to ed=20080101-20141021 (13)
Appendix 3. EMBASE search strategy
1996 to 2014 Week 42
1 Clinical trial/ (687540)
2 Randomized controlled trial/ (306414)
3 Randomization/ (55320)
4 Single blind procedure/ (17566)
5 Double blind procedure/ (91805)
6 Crossover procedure/ (36116)
7 Placebo/ (200584)
8 Randomi?ed controlled trial$.tw. (101060)
9 Rct.tw. (14607)
10 Random allocation.tw. (1055)
11 Randomly allocated.tw. (17036)
12 Allocated randomly.tw. (1316)
13 (allocated adj2 random).tw. (286)
14 Single blind$.tw. (11523)
15 Double blind$.tw. (102885)
16 ((treble or triple) adj blind$).tw. (337)
17 Placebo$.tw. (158223)
18 Prospective study/ (242685)
19 or/1-18 (1162726)
20 Case study/ (25629)
21 Case report.tw. (196639)
22 Abstract report/ or letter/ (563718)
23 or/20-22 (780796)
24 19 not 23 (1132564)
25 exp enteral nutrition/ (15911)
26 (enter$ adj3 feed$).tw. (5886)
27 (enter$ adj3 nutrit$).tw. (8814)
28 or/25-27 (19640)
29 exp Intubation, Gastrointestinal/ (2924)
30 (nasoenteral$ or naso enteral$).tw. (117)
31 (esophag$ adj3 intubat$).tw. (449)
32 (oesophag$ adj3 intubat$).tw. (158)
33 (duoden$ adj3 intubat$).tw. (96)
34 (gastrointest$ adj3 intubat$).tw. (21)
35 (gastric adj3 intubat$).tw. (440)
36 (esophag$ adj3 catheter$).tw. (362)
37 (oesophag$ adj3 catheter$).tw. (91)
38 (duoden$ adj3 catheter$).tw. (134)
39 (stomach adj3 intubat$).tw. (58)
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40 (stomach adj3 catheter$).tw. (46)
41 (gastrointest$ adj3 catheter$).tw. (36)
42 (gastric adj3 catheter$).tw. (224)
43 exp gastrointestinal motility/ (14371)
44 exp gastric emptying/ (10625)
45 (stomach adj3 emptying).tw. (230)
46 (gastric adj3 emptying).tw. (8625)
47 (gastro$ adj3 motili$).tw. (3722)
48 (gastric adj3 motili$).tw. (2146)
49 or/29-48 (29479)
50 exp metoclopramide/ (12043)
51 (Metoclopramide or Cerucal or 5 Chloro 2 Methoxyprocainamide or Clodilion or Clopra or Del 1267 or Del1267 or Diber-
til or Duraclamid or Emenil or Emetard or Emitasol or Encil or Gastrobid or Gastronerton or Gastrosil or Gastrotem or Gastro
Timelets or Gastrotimelets or Hyrin or M 813 or M813 or Maxeran or Maxeron or Maxolan or Maxolon or Meclopamide or Meclo-
pramide or Meclopran or Metaclopramide or Methochlopramide or Methoclopramide or Methoclopramine or Metochlopramide or
Metoclopamide or Metoclopramid or Metoclopramine or Metoclopranide Hydrochloride or Metaclopromide or Metoclorpramide or
Metodopramide or Metopram or Metox or Metpamid or Mygdalon or Neu Sensamide or Octamide or Paspertin or Perinorm or Plasil
or Pramidin or Pramin or Primperan or Reclomide or Reglan or Rimetin or Sensamide or Tomid).tw. (3489)
52 or/50-51 (12282)
53 28 and 49 and 52 (154)
54 24 and 53 (60)
55 limit 54 to em=200801-201442 (22)
Appendix 4. LILACS search strategy
(tw:(Metoclopramide or Cerucal or 5 Chloro 2 Methoxyprocainamide or Clodilion or Clopra or Del 1267 or Del1267 or Diber-
til or Duraclamid or Emenil or Emetard or Emitasol or Encil or Gastrobid or Gastronerton or Gastrosil or Gastrotem or Gastro
Timelets or Gastrotimelets or Hyrin or M 813 or M813 or Maxeran or Maxeron or Maxolan or Maxolon or Meclopamide or Meclo-
pramide or Meclopran or Metaclopramide or Methochlopramide or Methoclopramide or Methoclopramine or Metochlopramide or
Metoclopamide or Metoclopramid or Metoclopramine or Metoclopranide Hydrochloride or Metaclopromide or Metoclorpramide or
Metodopramide or Metopram or Metox or Metpamid or Mygdalon or Neu Sensamide or Octamide or Paspertin or Perinorm or Plasil
or Pramidin or Pramin or Primperan or Reclomide or Reglan or Rimetin or Sensamide or Tomid)) AND (year˙cluster:(2008-2014))
WH A T ’ S N E W
Last assessed as up-to-date: 21 October 2014.
Date Event Description
21 October 2014 New citation required but conclusions have not
changed
Literature search was re-run, with 58 new studies iden-
tified, no new studies fitted the inclusion criteria
21 October 2014 New search has been performed Updated format of review to current standards, conclu-
sions unchanged
New author (CB) added.
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H I S T O R Y
Protocol first published: Issue 4, 2001
Review first published: Issue 4, 2002
Date Event Description
10 December 2008 New search has been performed Updated
30 October 2008 New search has been performed Converted to new review format.
14 October 2005 Amended New studies sought but none found
23 August 2004 New search has been performed Minor update
5 August 2002 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
All authors, Cristiane Costa Reis da Silva, Humberto Saconato, Álvaro N Atallah, contributed equally to the production of the review
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produced in 2014.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In this updated review, we no longer use the Jadad scale to assess methodological quality (Jadad 1996). Instead we independently
assessed the risk of bias in the included studies using the risk of bias assessment tool described in Chapter 8 of theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
For the update in 2014 the authors CCRS and CB re-extracted data from all of the included studies and provided full assessments of
the risk of bias. We compared the evaluations, and if there had been any inconsistencies we would have and discussed and resolved
them.
We expanded the methods section to comply with current conduct and reporting standards for systematic reviews, including the
’Methodological Expectations of Cochrane Intervention Reviews’ (MECIR). The methods were implied in previous published version
of the review, but for clarity, the details are now stated explicitly. We describe how we planned to deal with assessment of risk of bias,
measures of treatment effect, unit of analysis issues, dealing with missing data, assessment of heterogeneity, data synthesis, subgroup
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analysis and sensitivity analysis. In our review there were too few included studies to permit assessment of reporting bias, or any
sensitivity analyses.
We present results as risk ratios (RR) in the updated version of the review (previously odds ratios (OR)).
We carried out Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessments of quality and present
a ’Summary of findings’ table that includes this assessment.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antiemetics [∗therapeutic use]; Enteral Nutrition [∗instrumentation]; Gastric Emptying; Injections, Intravenous; Intubation, Gas-
trointestinal [∗methods]; Metoclopramide [∗therapeutic use]; Pylorus; Randomized Controlled Trials as Topic
MeSH check words
Humans
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